

Table 1. Patient characteristics of ER+HER2- breast cancer patients primarily treated with surgery (n = 4.229)

Variable	Number of patients (n, %)	Points assigned
Age (years)		
mean (standard deviation)	59.5 (13.1)	NA
median (range)	59.0 (22-95)	NA
Pathological T stage		
T1	2.686 (63.5)	0
T2	1.415 (33.5)	0
T3	128 (3.0)	1
Pathological N stage		
N0	2.586 (61.2)	0
N1mic	181 (4.3)	0
N1	1.016 (24.0)	0
N2	289 (6.8)	2
N3	157 (3.7)	3
Anatomic stage		
I (A and B)	2.041 (48.3)	
IIA	1.209 (28.6)	
IIB	499 (11.8)	
IIIA	323 (7.6)	
IIIC	157 (3.7)	NA
ER status		
positive	4.229 (100.0)	0
negative	0 (0.0)	1
HER2 status		
positive	0 (0.0)	0
negative	4,229 (100.0)	1
PR status		
positive	3.504 (82.9)	NA
negative	725 (17.1)	
Nuclear grade		
I	1.205 (28.5)	0
II		0

III	2.106 (49.8) 918 (21.7)	1
Breast surgery		
breast-conserving surgery	2.525 (59.7)	
mastectomy	1.704 (40.3)	NA
Adjuvant CT		
no	2.871 (67.9)	
yes	1.358 (32.1)	NA
Adjuvant HT		
no	1.863 (44.1)	
yes	2.366 (55.9)	NA

N number, T tumor stage, N nodal stage, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, CT chemotherapy, HT hormone therapy